Page 226 - 2020_07-Haematologica-web

B. Paulsen et al. 3484-3488.
7. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous throm- bosis among patients with cancer. Arch Intern Med. 2004;164(15):1653-1661.
8. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reac- tivity: a systematic review. Arch Intern Med. 2003;163(19):2368-2392.
9. Noble S, Pasi J. Epidemiology and patho- physiology of cancer-associated thrombo- sis. Br J Cancer. 2010;102 Suppl 1:S2-9.
10. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboem- bolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346.
11. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
12. Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, Christensen K. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology. 2003;14(3):328-332.
13. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet. 2000;67(6):1452-1459.
14. Uitte de Willige S, de Visser MC, Houwing- Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fib- rinogen gamma gene increases the risk for deep venous thrombosis by reducing plas- ma fibrinogen gamma' levels. Blood. 2005;106(13):4176-4183.
15. Uitte de Willige S, Pyle ME, Vos HL, et al. Fibrinogen gamma gene 3'-end polymor- phisms and risk of venous thromboem- bolism in the African-American and Caucasian population. Thromb Haemost. 2009;101(6):1078-1084.
16. Grunbacher G, Weger W, Marx-Neuhold E, et al. The fibrinogen gamma (FGG) 10034C > T polymorphism is associated with venous thrombosis. Thromb Res. 2007;121(1):33-36.
17. Germain M, Saut N, Greliche N, et al. Genetics of venous thrombosis: insights from a new genome wide association study. PLoS One. 2011;6(9):e25581.
18. Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734 individuals identi- fies TSPAN15 and SLC44A2 as two suscep- tibility loci for venous thromboembolism. Am J Hum Genet. 2015;96(4):532-542.
19. El-Galaly TC, Severinsen MT, Overvad K, et al. Single nucleotide polymorphisms and the risk of venous thrombosis: results from
a Danish case-cohort study. Br J Haematol.
2013;160(6):838-841.
20. Folsom AR, Tang W, George KM, et al.
Prospective study of gamma' fibrinogen and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). Thromb Res. 2016;139:44-49.
21. Jiang J, Liu K, Zou J, et al. Associations between polymorphisms in coagulation- related genes and venous thromboem- bolism: A meta-analysis with trial sequen- tial analysis. Medicine (Baltimore). 2017; 96(13):e6537.
22. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic muta- tions, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
23. Pabinger I, Ay C, Dunkler D, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost. 2015;13(1):17-22.
24. Gran OV, Smith EN, Braekkan SK, et al. Joint effects of cancer and variants in the Factor 5 gene on the risk of venous throm- boembolism. Haematologica. 2016; 101(9):1046-1053.
25. Gran OV, Braekkan SK, Hansen JB. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res. 2018;164 Suppl 1:S12-S18.
26. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso Study. Int J Epidemiol. 2012; 41(4):961-967.
27. Blix K, Severinsen MT, Braekkan S, et al. Cancer-related venous thromboembolism in the general population: results from the Scandinavian Thrombosis and Cancer (STAC) study. J Thromb Haemost. 2015;13:(Suppl 2):549-549.
28. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782-1787.
29. Morange PE, Tregouet DA. Lessons from genome-wide association studies in venous thrombosis. J Thromb Haemost. 2011;9(Suppl 1):258-264.
30. Ramacciotti E, Wolosker N, Puech-Leao P, et al. Prevalence of factor V Leiden, FII G20210A, FXIII Va134Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 2003;109(4):171-174.
31. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A pro- thrombin mutation and the risk of subcla- vian vein thrombosis in patients with breast cancer and a central venous catheter.
Ann Oncol. 2004;15(4):590-593.
32. Rosendaal FR. Venous thrombosis: a multi- causal disease. Lancet. 1999;
353(9159):1167-1173.
33. Willige SU, Rietveld IM, De Visser MCH,
Vos HL, Bertina RM. Polymorphism 10034C > T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gamma A mRNA ratio. J Thromb Haemost. 2007;5(6):1243-1249.
34. Farrell DH. gamma' Fibrinogen as a novel marker of thrombotic disease. Clin Chem Lab Med. 2012;50(11):1903-1909.
35. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol. 2007;139(3):494-503.
36. Omarova F, Uitte De Willige S, Ariens RA, Rosing J, Bertina RM, Castoldi E. Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma'. J Thromb Haemost. 2013;11(9):1669-1678.
37. Lovely RS, Rein CM, White TC, et al. gammaA/gamma' fibrinogen inhibits thrombin-induced platelet aggregation. Thromb Haemost. 2008;100(5):837-846.
38. Omarova F, Uitte de Willige S, Simioni P, et al. Fibrinogen gamma' increases the sensi- tivity to activated protein C in normal and factor V Leiden plasma. Blood. 2014; 124(9):1531-1538.
39. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary pro- phylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2012;(2):CD008500.
40. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.
41. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33(6):654-656.
42. Brand JS, Hedayati E, Humphreys K, et al. Chemotherapy, genetic susceptibility, and risk of venous thromboembolism in breast cancer patients. Clin Cancer Res. 2016;22(21):5249-5255.
43. Munoz Martin AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018; 118(8):1056-1061.
1968
haematologica | 2020; 105(7)